Skip to main content

Table 1 The relationship between ERβ/IL6 expression levels and clinical characteristics of NSCLC patients

From: 17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression

  No. of patients(%) ERβ Expression χ2 p value IL6 Expression χ2 p value
Positive Negative Positive Negative
All 289 258 31    270 19   
Gender
 Female 102(35.29) 95 7 2.458 0.117 99 3 3.388 0.066
 Male 187(64.71) 163 24    171 16   
Age
  < 60 170(58.82) 150 20 0.465 0.495 158 12 0.158 0.691
  ≥ 60 119(41.18) 108 11    112 7   
Smoking
 Ex 178(61.59) 162 16 1.462 0.227 171 7 5.266 0.022
 Never 111(38.41) 96 15    99 12   
T stage
 1a-2b 220 (76.12) 194 26 1.146 0.284 205 15 0.089 0.765
 3–4 69 (23.88) 64 5    65 4   
Lymph node metastasis
 YES 187(64.71) 167 20 0.001 0.974 178 9 2.677 0.102
 NO 102(35.29) 91 11    92 10   
Metastasis
 YES 24(08.30) 18 6 5.568 0.018 20 4 4.34 0.037
 NO 265(91.70) 240 25    250 15   
TNM stage
 I-II 175 (60.55) 154 21 0.751 0.386 162 13 0.527 0.468
 III-IV 114(39.45) 104 10    108 6   
Tumor Histology
 SQC 134(46.37) 115 19 3.11 0.078 125 9 0.008 0.92873
 ADC 155(53.63) 143 12    145 10   
Tumor Differentation
 Well/Moderate 156(53.98) 134 22 4.034 0.045 141 15 5.104 0.024
 Poor 133(46.02) 124 9    129 4   
  1. P values listed are derived from χ2 test